Recent advances for the treatment of cocaine abuse: Central nervous system immunopharmacotherapy

AAPS Journal

Volumn 7, Issue 3, 2005, Pages

  Dickerson, Tobin J ^a   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Central nervous system; Cocaine; Immunopharmacotherapy; Phage display; Virus

Indexed keywords

BACLOFEN; CABERGOLINE; CARBOXYLESTERASE; CHOLINESTERASE; COCAINE; DISULFIRAM; ILLICIT DRUG; MODAFINIL; PROTEIN DERIVATIVE; RESERPINE; SELEGILINE; SERTRALINE; TIAGABINE; TOPIRAMATE; VIRUS ANTIBODY; CENTRAL NERVOUS SYSTEM AGENTS;

ARTICLE; BACTERIOPHAGE M13; CATALYSIS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG BINDING; DRUG SYNTHESIS; GOVERNMENT; HEALTH EDUCATION; HUMAN; IMMUNIZATION; IMMUNOPHARMACOLOGY; IN VIVO STUDY; NONHUMAN; PROTEIN BINDING; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; SYMPTOM; ANIMAL; BACTERIOPHAGE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOTOR ACTIVITY; REVIEW;

ANIMALS; BACTERIOPHAGES; CENTRAL NERVOUS SYSTEM AGENTS; COCAINE-RELATED DISORDERS; HUMANS; IMMUNOTHERAPY; MOTOR ACTIVITY;

EID: 33644806661     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070359     Document Type: Article

References (61)

1. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci. 2000;909:170-185.
2. Weiss F, Koob GF. Drug addiction: functional neurotoxicity of the brain reward systems. Neurotoxic Res. 2001;3:145-156.
3. Melichar JK, Daglish MRC, Nutt DJ. Addiction and withdrawal-current views. Curr Opin Pharmacol. 2001;1:84-90.
4. Spanagel R, Weiss F. The dopanamine hypothesis of reward: past and current status. Trends Neurosci. 1999;22:521-527.
5. Di Chiana G. The role of dopanamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 1995;38:95-137.
6. Johanson C-E, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev. 1989;41:3-52.
7. Blaine JD, Ling W. Psychopharmacologic treatment of cocaine dependence. Psychopharmacol Bull. 1992;28:11-14.
8. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Preliminary estimates from the 1992 Household Survey on Drug Abuse, Advance Report No. 3. Washington, DC: US Department of Health and Human Services, Public Health Service; June 1993.
9. Cregler LL, Herbert M. Medical complications of coccaine abuse. N Engl J Med. 1986;315:1495-1500.
10. Des Jarlais DC, Friedman SR. AIDS and i.v. drug use. Science. 1989;245:578-579.
11. Lee Jh, Bennett G. Substance abuse in adulthood. In: Bennett G, Woolf D, eds. Substance Abuse: Pharmacologic, Developmental and Clinical Perspectives. Albany: Delman Publishing; 1991:157-170.
12. Walsh SL. Behavioral pharmacology of cocaine. In: Tarter RE, Ammerman RT, Ott PJ, eds. Handbook of Substance Abuse: Neurobehavioral Pharmacology. New York: Plenum: 1998:187-200.
13. Mendelson JH, Mello NK. Management of cocaine abuse and dependence. N Engl J Med. 1996;334:965-972
14. Gorelick DA. Pharmacologic interventions for cocaine, crack, and other stimulant addiction. In: Graham AW, Schultz TK, eds. Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 2003:89-111.
15. Gorelick DA. Gardner EL, Xi Z-X. Agents in the development for the management of cocaine abuse. Drugs. 2004;64:1547-1573.
16. Leiderman DB, Shoptaw S, Montgomery A, et al. Cocaine rapid efficacy screening trial (CREST). A paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction. 2005;100:1-11.
17. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction. 2005;100:68-77.
18. Gonzales G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003;98:1625-1632.
19. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2004;61:264-272.
20. Houtsmuller EJ, Notes LD, Newton T, et al. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl). 2004;172:31-40.
21. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use, J Clin Psychiatry. 2003;64:1440-1448.
22. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75:223-240.
23. Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. 2001;63:69-78.
24. Hoffman JA, III, Caudill BD, III, Koman JJ, III, Luckey JW, Flynn PM, Hubbard RL. Comparative cocaine abuse treatment strategies: enhancing client retention and treatment exposure. J Addict Dis. 1994;13:115-128.
25. Caashman JR. Biocatalysts in detoxication of drugs of abuse. NIDA Res Monogr. 1997;173:225-258.
26. Carrera MRA, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Suppression of psychoactive effects of cocaine by active immunization, Nature. 1995;378:727-730.
27. Carrera MRA, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model. Prot Natl Acad Sci USA. 2000;97:6202-6206.
28. Carrera MRA, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA. 2001;98:1988-1992.
29. Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med. 1996;2:1129-11132.
30. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl). 2000; 148:251-262.
31. Landry DW, Zhao K, Yang GX-P, Glickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine. Science. 1993;259:1899-1901.
32. Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J Pharmacol Exp Ther. 2000;293:952-961.
33. Yang G, Chun J, Arakawa-Uramoto H, et al. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J Am Chem Soc. 1996; 118:5880-5890.
34. Baird TJ, Deng S-X, Landry DW, Winger G, Woods JH. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther. 2000;295:1127-1134.
35. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg Med Chem Lett. 2001;11:87-90.
36. Isomura S, Hoffman TZ, Wirsching P, Janda KD. Synthesis, properties, and reactivity of cocaine benzoylthioester possessing the cocaine absolute configuration. J Am Chem Soc. 2002;124:3661-3668.
37. Meijler MM, Matsushita M, Wirsching P, Janda KD. Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Tech. 2004;1:77-89.
38. Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2004;3:11-18.
39. Gorelick DA. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 1997;48:159-165.
40. Mattes CE, Belendiuk GW, Lynch TJ, Brady RO, Dretchen KL. Butyryleholinesterase: an enzyme antidote for cocaine intoxication. Addict Biol. 1998;3:171-188.
41. Nachon F, Nicolet Y, Viquie N, Masson P, Fontecilla-Camps JD, Lockridge O. Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization. Eur J Biochem. 2002;269:630-637.
42. Mattes CE, Lynch TJ, Singh A, et al. Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol. 1997;145:372-380.
43. Sun H, Pang Y-P, Lockridge O, Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol. 2002;62:220-224.
44. Larocca D, Burg MA, Jensen-Pergakes K, Ravey PE, Gonzales AM, Baird A. Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol. 2002;3:45-57.
45. Smith GP. Filamentous fusion phage; novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315-1317.
46. Carlton RM. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz). 1999;47:267-274.
47. Smith HW, Huggins RB. Successful treatment of experimental E coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol. 1982:128:307-318.
48. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowski A. Results in bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz). 1986;35:569-583.
49. Stone R. Stalin's forgotten cure. Science. 2002;298:728-731,
50. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996;380:364-366.
51. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculatures. Proc Natl Acad Sci USA. 2002;99:2252-2257.
52. Dabrowska K, Switala-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A. Bacteriophage penetration in vertebrates. J Appl Microbiol. 2005;98:7-13.
53. Frenkel D, Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci USA. 2002;99-5675-5679.
54. Gao C, Mao S, Lo C-HL, Wirsching P, Lerner RA, Janda KD. Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays Proc. Natl Acad Sci USA 1999-96-6025-6030.
55. Gao C, Mao S, Kaufmann G, Wirsching P, Lerner RA, Janda KD. A method for the generation of combinatorial antibody libraries using pIX phage display. Proc Natl Acad Sci USA. 2002;99:12612-12616.
56. Carrera MRA, Kaufmann GF, Mee JM, Meijler MM, Koob GF, Janda KD. Treating cocaine addiction with viruses. Proc Natl Acad Sci USA. 2004;101:10416-10421.
57. Barbas CF, Burton DR, Scott JK, Silverman GJ. Phage Display: A Laboratory Manual. Tuebingen, Germany: Cold Spring Harbor Laboratory Press; 2001.
58. Lyon M, Robbins TW. The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In: Essman W, Valzelli L, eds. Current Developments in Psychopharmacology. vol. 4. New York: Spectrum; 1975:79-163.
59. Illum L, Davis SS. Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Deliv Rev. 2001;51.97-111.
60. Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev. 2001;51:5-19.
61. Bresler MM, Rosser SJ, Basran A, Bruce NC. Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp strain MB1. Appl Environ Microbiol. 2000;66:904-908.